Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay

Journal of Virology

Volumn 73, Issue 7, 1999, Pages 5356-5363

  Kosalaraksa, Pope ^a   Kavlick, Mark F ^a   Maroun, Victor ^a   Le, Richard ^a   Mitsuya, Hiroaki ^a,b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIDANOSINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; GENETIC RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; STRUCTURAL GENE; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0033064963     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.7.5356-5363.1999     Document Type: Article

References (31)

1. Caliendo, A. M., A. Savara, D. An, K. DeVore, J. C. Kaplan, and R. T. D'Aquila. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
2. D'Aquila, R. T., V. A. Johnson, S. L. Welies, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. Crumpacker, J. O. Kahn, and D. D. Richman. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
3. De Clercq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses 8:119-134.
4. De Clercq, E. 1995. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:200-239.
5. De Simone, V., G. La Mantia, L. Lania, and P. Amati. 1985. Polyomavirus mutation that confers a cell-specific cis advantage for viral DNA replication. Mol. Cell. Biol. 5:2142-2146.
6. Erice, A., and H. H. J. Balfour. 1994. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clin. Infect. Dis. 18:149-156.
7. Gomez-Cano, M., A. Rubio, T. Puig, M. Perez-Olmeda, L. Ruiz, V. Soriano, J. A. Pineda, L. Zamora, N. Xaus, B. Clotet, and M. Leal. 1998. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 12:1015-1020.
8. Harrigan, P. R., S. Bloor, and B. A. Larder. 1998. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72:3773-3778.
9. Harrigan, P. R., I. Kinghorn, S. Bloor, S. D. Kemp, I. Najera, A. Kohli, and B. A. Larder. 1996. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70:5930-5934.
10. Iversen, A. K., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
11. Johnson, V. A. 1995. Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. J. Infect. Dis. 171:S140-S149.
12. Kavlick, M. F., K. Wyvill, R. Yarchoan, and M. Mitsuya. 1998. Emergency of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J. Infect. Dis. 177:1506-1513.
13. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66: 2232-2239.
14. Kozal, M. J., K. Kroodsma, M. A. Winters, R. W. Shafer, B. Efron, D. A. Katzenstein, and T. C. Merigan. 1994. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann. Intern. Med. 121:263-268.
15. Kozal, M. J., R. W. Shafer, M. A. Winters, D. A. Katzenstein, and T. C. Merigan. 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:526-532.
16. Lacey, S. F., and B. A. Larder. 1994. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance. J. Virol. 68:3421-3424.
17. Larder, B. A. 1994. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:951-957.
18. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
19. Maeda, Y., D. J. Venzon, and H. Mitsuya. 1998. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177: 1207-1213.
20. Mitsuya, H., and R. Yarchoan. 1994. Development of antiretroviral therapy for AIDS and related disorders, p. 721-742. In S. Broder, T. Merigan, and D. Bolognesi (ed.), Textbook of AIDS medicine. Williams & Wilkins, Baltimore, Md.
21. Moutouh, L., J. Corbeil, and D. D. Richman. 1996. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc. Natl. Acad. Sci. USA 93:6106-6111.
22. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
23. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37: 1207-1213.
24. Schmit, J.-C., J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1996. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 174:962-968.
25. Shafer, R. W., A. K. Iversen, M. A. Winters, E. Aguiniga, D. A. Katzenstein, and T. C. Merigan. 1995. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172: 70-78.
26. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. R. Meyer, P. Gupta, S. Rasbeed, R. Coombs, M. Katzman, S. Fiscuss, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
27. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuja. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 14:2398-2402.
28. Shirasaka, T., R. Yarchoan, M. C. O'Brien, R. N. Husson, B. D. Anderson, E. Kojima, T. Shimada, S. Broder, and H. Mitsuya. 1993. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. USA 90:562-566.
29. Ueno, T., and H. Mitsuya. 1997. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2′,3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 34:1092-1099.
30. Ueno, T., T. Shirasaka, and H. Mitsuya. 1995. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J. Biol. Chem. 270:23605-23611.
31. Yusa, K., M. F. Kavlick, P. Kosalaraksa, and H. Mitsuya. 1997. HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination. Antiviral Res. 36:179-189.